Lv51
998 积分 2024-09-18 加入
Cancer burden and control in China: landscape, trends and challenges
1个月前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
2个月前
已完结
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
2个月前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
10个月前
已完结
A pooled analysis of datopotamab deruxtecan in patients with EGFR–mutated NSCLC
10个月前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
10个月前
已完结
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
1年前
已完结
皖公网安备34019202002308
